CYTARABINE PLUS IDARUBICIN OR DAUNORUBICIN AS INDUCTION AND CONSOLIDATION THERAPY FOR PREVIOUSLY UNTREATED ADULT PATIENTS WITH ACUTE MYELOID-LEUKEMIA

被引：1
|
作者：
WIERNIK, PH
BANKS, PLC
CASE, DC
ARLIN, ZA
PERIMAN, PO
TODD, MB
RITCH, PS
ENCK, RE
WEITBERG, AB
机构：
[1] ADRIA LABS INC, COLUMBUS, OH USA
[2] MAINE MED CTR, PORTLAND, ME 04102 USA
[3] NEW YORK MED COLL, VALHALLA, NY 10595 USA
[4] HARRINGTON CANC CTR, AMARILLO, TX USA
[5] YALE UNIV, SCH MED, NEW HAVEN, CT 06510 USA
[6] MED COLL WISCONSIN, MILWAUKEE, WI 53226 USA
[7] RIVERSIDE CANC INST, COLUMBUS, OH USA
[8] ROGER WILLIAMS GEN HOSP, PROVIDENCE, RI 02908 USA
来源：
BLOOD | 1992年 / 79卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：313 / 319
页数：7
相关论文
共 50 条
  • [31] Meta-Analysis of Randomised Clinical Trials Comparing Idarubicin plus Cytarabine with Daunorubicin plus Cytarabine as the Induction Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukaemia
    Wang, Jing
    Yang, Yong-Gong
    Zhou, Min
    Xu, Jing-Yan
    Zhang, Qi-Guo
    Zhou, Rong-Fu
    Chen, Bing
    Ouyang, Jian
    [J]. PLOS ONE, 2013, 8 (04):
  • [32] Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide, and carboplatin
    Bow, EJ
    Gallant, G
    Williams, GJ
    Woloschuk, D
    Shore, TB
    Rubinger, M
    Schacter, BA
    [J]. CANCER, 1998, 83 (07) : 1344 - 1354
  • [33] Clinical Outcome of Management of Acute Myeloid Leukemia with Idarubicin plus Cytarabine
    Hafeez, M.
    Shaharyar
    Shabbir, K.
    Alauddin, Z.
    Farooq, M.
    [J]. ANNALS OF KING EDWARD MEDICAL UNIVERSITY LAHORE PAKISTAN, 2005, 11 (04): : 519 - 520
  • [34] TREATMENT OF RELAPSED ACUTE MYELOID-LEUKEMIA WITH IDARUBICIN AND INTERMEDIATE-DOSE CYTARABINE
    HAROUSSEAU, JL
    REIFFERS, J
    HURTELOUP, P
    MILPIED, N
    GUY, H
    RIGALHUGUET, F
    FACON, T
    DUFOUR, P
    IFRAH, N
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (01) : 45 - 49
  • [35] Phase I Trial of Escalating Doses of the Bcl-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia (AML)
    Stone, Richard M.
    DeAngelo, Daniel J.
    Galinsky, Ilene
    Kokulis, Caroline
    Stewart, Jeremy M.
    McGinnis, Michael
    Werner, Lillian
    Letai, Anthony G.
    Konopleva, Marina Y.
    Luskin, Marlise
    [J]. BLOOD, 2019, 134
  • [36] IDARUBICIN - A PHARMACOECONOMIC EVALUATION OF ITS USE IN ADULT PATIENTS WITH ACUTE MYELOID-LEUKEMIA
    WHITTINGTON, R
    GOA, KL
    [J]. PHARMACOECONOMICS, 1993, 4 (04) : 287 - 307
  • [37] Induction of acute myeloid leukemia (AML) with idarubicin, cytarabine and cladribine (ICC).
    Wiedower, Eric
    Jamy, Omer Hassan
    Martin, Michael Gary
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [38] ACUTE MYELOID-LEUKEMIA - IS CONSOLIDATION THERAPY NECESSARY
    WORSLEY, AM
    GALTON, DAG
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1984, 56 (03) : 361 - 364
  • [39] Venetoclax plus cyclophosphamide and cytarabine as induction regimen for adult acute myeloid leukemia
    Zhang, Baohang
    Liu, Qingguo
    Li, Junfan
    Hu, Yimin
    Zhao, Xin
    Huang, Pingping
    Li, Shangzhu
    Wang, Ying
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [40] ORAL IDARUBICIN IN ELDERLY PATIENTS WITH ACUTE MYELOID-LEUKEMIA
    KELDSEN, N
    KARLE, H
    HANSEN, NE
    NISSEN, NI
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 1990, 45 (01) : 60 - 60
12345